CDXSNasdaqIndustrial Organic ChemicalsFiscal year ends December 31
CODEXIS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.32+0.08 (+6.45%)
Close on Oct 19, 2026
- Market cap
- $120.19M
- P/E (TTM)
- –
- Dividend yield
- –
CODEXIS, INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novel Biotherapeutics | – | – | – | – | – | – | – | – | – | – | – | $567.00K | – | – |
| Performance Enzymes | – | – | – | – | – | – | – | – | – | – | – | $8.71M | – | – |
| Novel Biotherapeutics | – | – | – | – | – | – | – | – | – | – | – | $567.00K | – | – |
| Performance Enzymes | – | – | – | – | – | – | – | – | – | – | – | $8.71M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novel Biotherapeutics | – | – | – | – | – | – | – | – | – | – | – | -$6.19M | – |
| Performance Enzymes | – | – | – | – | – | – | – | – | – | – | – | -$4.62M | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $13.22M | $7.19M | $5.78M | $6.81M | $7.38M | $6.06M | $9.82M | $11.16M | $6.26M | $9.55M | $18.10M | $5.40M | 88.6% | +79.1% |
| Research and development revenue | $1.70M | $8.06M | – | $1.79M | $7.95M | $1.48M | $11.64M | $1.68M | $1.72M | – | $8.46M | $3.88M | 11.4% | -78.6% |
| Product revenue | – | – | – | – | – | – | – | – | – | $9.55M | – | – | – | – |
| Research and development revenue | – | – | – | – | – | $1.48M | – | – | – | $7.52M | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APAC | $11.74M | $5.33M | – | $6.06M | $6.58M | $1.54M | – | $9.07M | $4.97M | $7.26M | – | $1.81M | 78.7% | +78.4% |
| Americas | $1.72M | $7.86M | $33.53M | $1.57M | $6.35M | $2.09M | $11.46M | $1.53M | $1.05M | $7.24M | $2.94M | $4.28M | 11.5% | -72.9% |
| EMEA | $1.45M | $2.06M | $2.01M | $972.00K | $2.40M | $3.92M | $3.59M | $2.23M | $1.97M | $2.57M | $8.28M | $3.19M | 9.7% | -39.4% |
From the segment and revenue-disaggregation notes of Codexis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.